Jounce Therapeutics, a preclinical immuno-oncology biotech targeting inducible T-cell co-stimulators, filed on Friday with the SEC to raise up to $75 million in an initial public offering.
The Cambridge, MA-based company was founded in 2012 and booked $17 million in sales for the 12 months ended September 30, 2016. It plans to list on the Nasdaq under the symbol JNCE. J.P. Morgan and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
The article Biotech Jounce Therapeutics files for a $75 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
